Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
Systematic review	183 people Data from 1 RCT	Difference in percentage of people clinically improved short term with haloperidol (range 2–8 mg/day, mean daily dose 5.6 mg/day) with risperidone (range 2–8 mg/day, mean daily dose 6.1 mg/day) Absolute results not reported	Difference 12% P <0.05	Effect size not calculated	risperidone
Systematic review	183 people Data from 1 RCT	Difference in percentage of people withdrawing because of adverse events with haloperidol (range 2–8 mg/day, mean daily dose 5.6 mg/day) with risperidone (range 2–8 mg/day, mean daily dose 6.1 mg/day) Absolute results not reported	Difference 18% P = 0.02	Effect size not calculated	risperidone
Systematic review	183 people Data from 1 RCT	Difference in percentage of patients requiring antiparkinsonian medication with haloperidol (range 2–8 mg/day, mean daily dose 5.6 mg/day) with risperidone (range 2–8 mg/day, mean daily dose 6.1 mg/day) Absolute results not reported	Difference 25% P <0.001	Effect size not calculated	risperidone
Systematic review	183 people Data from 1 RCT	Difference in percentage of patients with non-extrapyramidal adverse events short term with haloperidol (range 2–8 mg/day, mean daily dose 5.6 mg/day) with risperidone (range 2–8 mg/day, mean daily dose 6.1 mg/day) Absolute results not reported	Difference 3% P value not reported
Systematic review	555 people Data from 1 RCT	Difference in mean increase in body weight short term with haloperidol (range 1–4 mg/day, mean modal dose 2.9 mg/day) with risperidone (range 1–4 mg/day, mean modal dose 3.3 mg/day) Absolute results not reported	Difference 1.6 kg P = 0.03	Effect size not calculated	haloperidol
Systematic review	555 people Data from 1 RCT	Difference in percentage of patients withdrawing because of adverse events long term with haloperidol (range 1–4 mg/day, mean modal dose 2.9 mg/day) with risperidone (range 1–4 mg/day, mean modal dose 3.3 mg/day) Absolute results not reported	Difference 0.7% P = 0.71		Not significant
Systematic review	555 people Data from 1 RCT	Difference in percentage of patients with persistent dyskinesia long term with haloperidol (range 1–4 mg/day, mean modal dose 2.9 mg/day) with risperidone (range 1–4 mg/day, mean modal dose 3.3 mg/day) Absolute results not reported	Difference 1.5% P = 0.28		Not significant
RCT	289 inpatients with first-episode schizophrenia	Prevalence of movement disorder adverse effects (Simpson-Angus Scale total score >0) 8 weeks with haloperidol (mean daily dose 3.7 mg/day) with risperidone (mean daily dose 3.8 mg/day) Absolute results not reported	OR 1.32 P = 0.036	Small effect size	risperidone
RCT	289 inpatients with first-episode schizophrenia	Prevalence of movement disorder adverse effects (Abnormal Involuntary Movement Scale total score >0) 8 weeks with haloperidol (mean daily dose 3.7 mg/day) with risperidone (mean daily dose 3.8 mg/day) Absolute results not reported	OR 1.42 P = 0.004	Small effect size	risperidone
RCT	289 inpatients with first-episode schizophrenia	Prevalence of movement disorder adverse effects (Hillside Akathisia Scale total score >0) 8 weeks with haloperidol (mean daily dose 3.7 mg/day) with risperidone (mean daily dose 3.8 mg/day) Absolute results not reported	OR 1.28 P = 0.103		Not significant
Systematic review	2783 people 21 RCTs in this analysis	Extrapyramidal symptoms with haloperidol with risperidone Absolute results not reported	RR 0.61 95% CI 0.52 to 0.72	Small effect size	risperidone
Systematic review	1336 people 9 RCTs in this analysis	Mean difference in weight gain (kg) with haloperidol with risperidone Absolute results not reported	Mean difference 1.7 kg 95% CI 0.9 kg to 2.4 kg	Effect size not calculated	haloperidol
Systematic review	2914 people 15 RCTs in this analysis	Sedation with haloperidol with risperidone Absolute results not reported	RR 0.86 95% CI 0.70 to 1.05		Not significant
Systematic review	397 people Data from 1 RCT	Change from baseline in Extrapyramidal Symptom Rating Scale total score +0.3 with haloperidol (11.7 mg/day) –0.1 with risperidone (4.9 mg/day)	P = 0.02	Effect size not calculated	risperidone
Systematic review	397 people Data from 1 RCT	Change from baseline in parkinsonism subscale +0.5 with haloperidol (11.7 mg/day) –0.7 with risperidone (4.9 mg/day)	P = 0.03	Effect size not calculated	risperidone
Systematic review	397 people Data from 1 RCT	Change from baseline in global impression score for parkinsonism +0.1 with haloperidol (11.7 mg/day) –0.3 with risperidone (4.9 mg/day)	P = 0.0002	Effect size not calculated	risperidone
Systematic review	397 people Data from 1 RCT	Change from baseline in global impression score for dyskinesia +0.1 with haloperidol (11.7 mg/day) –0.1 with risperidone (4.9 mg/day)	P = 0.03	Effect size not calculated	risperidone
Systematic review	397 people Data from 1 RCT	Change from baseline in weight gain (kg) 0.73 kg with haloperidol (11.7 mg/day) 2.3 kg with risperidone (4.9 mg/day)	P <0.001	Effect size not calculated	haloperidol